OBSOLETE: HIV-related lung cancer

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:443301
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

HIV-related lung cancer is a term that was previously used to describe lung cancer occurring in people living with HIV (human immunodeficiency virus). This condition is now considered 'obsolete' as a separate disease category in medical classification systems, meaning it is no longer listed as a distinct rare disease. Instead, lung cancer in people with HIV is generally managed as lung cancer with an underlying immune condition, rather than as a unique separate disease. People living with HIV have a higher risk of developing lung cancer compared to the general population. This increased risk is thought to be due to a combination of factors, including a weakened immune system, higher rates of smoking among people with HIV, chronic inflammation, and the effects of the virus itself on lung tissue. The most common type of lung cancer seen in this group is non-small cell lung cancer. Symptoms of lung cancer in people with HIV are similar to those in the general population and may include a persistent cough, coughing up blood, chest pain, shortness of breath, unexplained weight loss, and fatigue. Treatment typically involves a combination of antiretroviral therapy to manage HIV alongside standard cancer treatments such as surgery, chemotherapy, radiation, immunotherapy, or targeted therapy, depending on the type and stage of cancer.

Key symptoms:

Persistent or worsening coughCoughing up blood or blood-tinged mucusChest pain or tightnessShortness of breathUnexplained weight lossExtreme tiredness or fatigueLoss of appetiteHoarse voiceFrequent lung infections such as pneumoniaSwollen lymph nodes in the neck or chestBone pain if cancer has spread

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: HIV-related lung cancer.

View clinical trials →

No actively recruiting trials found for OBSOLETE: HIV-related lung cancer at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: HIV-related lung cancer community →

No specialists are currently listed for OBSOLETE: HIV-related lung cancer.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: HIV-related lung cancer.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: HIV-related lung cancerForum →

No community posts yet. Be the first to share your experience with OBSOLETE: HIV-related lung cancer.

Start the conversation →

Latest news about OBSOLETE: HIV-related lung cancer

1 articles
Clinical trialCLINICALTRIALSApr 14, 2026
Trial Now Recruiting: Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK) (NCT07524114)
Researchers are recruiting 7,000 cancer patients to test a new way of detecting cancer that comes back after treatment. By analyzing blood, tissue, and other bo
See all news about OBSOLETE: HIV-related lung cancer

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What type and stage of lung cancer do I have, and what does that mean for my treatment options?,How will my HIV medications interact with my cancer treatment, and will my antiretroviral therapy need to change?,Am I eligible for targeted therapy or immunotherapy based on my tumor's genetic profile?,How will my immune system (CD4 count) affect my ability to tolerate cancer treatment?,Should I be enrolled in any clinical trials specifically for people with HIV and lung cancer?,What support services are available to help me manage both HIV and cancer at the same time?,What symptoms should prompt me to seek emergency care during treatment?

Common questions about OBSOLETE: HIV-related lung cancer

What is OBSOLETE: HIV-related lung cancer?

HIV-related lung cancer is a term that was previously used to describe lung cancer occurring in people living with HIV (human immunodeficiency virus). This condition is now considered 'obsolete' as a separate disease category in medical classification systems, meaning it is no longer listed as a distinct rare disease. Instead, lung cancer in people with HIV is generally managed as lung cancer with an underlying immune condition, rather than as a unique separate disease. People living with HIV have a higher risk of developing lung cancer compared to the general population. This increased risk

At what age does OBSOLETE: HIV-related lung cancer typically begin?

Typical onset of OBSOLETE: HIV-related lung cancer is adult. Age of onset can vary across affected individuals.